• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Targeting Tim-1 to Circumvent Immune Tolerance in Prostate Cancer.
【24h】

Targeting Tim-1 to Circumvent Immune Tolerance in Prostate Cancer.

机译：针对Tim-1以减少前列腺癌中的免疫耐受。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Early-stage clinical testing raises the possibility that combinatorial approaches that augment tumor antigen-specific immune responses may accomplish significant tumor destruction without the induction of serious autoimmune disease. Accordingly, a rational and combinatorial manipulation of immune evasion pathways and their targets should aid in the development of safer and more effective vaccine strategies and immunotherapies for all stages of prostate cancer. In prostate cancer, a plausible combination that could be targeted towards patients who undergo androgen ablation, a therapeutic modality that is also known to enhance immune responses to prostate TAA, would include a vaccine in conjunction with biologic agents that are known to simultaneously augment antigen presentation by DCs and inhibit immunosuppressive cells such as regulatory T cells (Treg) or prolong the survival and enhance the vigor of tumor-specific lymphocytes. An example of such agents is the agonist antibody that targets TIM-1, a receptor expressed on lymphocytes and dendritic cells that enhances cytotoxic lymphocyte responses to tumor-associated antigens when used in combination with a vaccine. Here we explore the combination of androgen ablation and anti-TIM1 targeting as a strategy to ameliorate cancer-specific vaccine outcome in a mouse model of prostate cancer.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号